SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Miromatrix Medical Inc. MIRO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Miromatrix Medical Inc. (MIRO) is a Biotechnology company in the Healthcare sector, currently trading at $3.39. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is MIRO = $9 (+165.5% upside).

Financials: revenue is $953,470, +891.1%/yr average growth. Net income is $30M (loss), growing at -118.7%/yr. Net profit margin is -3147.2% (negative). Gross margin is 47.6% (+47.6 pp trend).

Balance sheet: total debt is $4M against $26M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 5.52 (strong liquidity). Debt-to-assets is 10.2%. Total assets: $35M.

Analyst outlook: 2 / 2 analysts rate MIRO as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 43/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

$9.00

▲ 165.49% Upside

Average Price Target

The 12-month price target for Miromatrix Medical Inc. is $9.00.

MIRO SharesGrow Score Overview

63/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 43/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MIRO

MIRO trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $9, implying +165.5% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

MIRO: +891.1%/yr revenue is, -118.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet MIRO: Debt-to-Equity (D/E) ratio 0.14 (conservative), Current ratio is 5.52 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

MIRO: Gross margin is 47.6% (+47.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 2 analysts rate MIRO as buy (100%). Analyst consensus target is $9 (+165.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

MIRO: Net profit margin is -3147.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.906-4.35

Volume631.56K

Avg Volume (30D)163.02K

Market Cap$92.95M

Beta (1Y)0.02

Share Statistics

EPS (TTM)-1.45

Shares Outstanding$20.73M

IPO Date2021-06-24

Employees76

CEOJeffrey James Ross

Financial Highlights & Ratios

Revenue (TTM)$953.47K

Gross Profit$453.47K

EBITDA$-29.91M

Net Income$-30.01M

Operating Income$-30.25M

Total Cash$25.2M

Total Debt$3.55M

Net Debt$-1.66M

Total Assets$34.76M

Price / Earnings (P/E)-2.3

Price / Sales (P/S)97.49

Analyst Forecast

1Y Price Target$9.00

Target High$9.00

Target Low$9.00

Upside+165.5%

Rating ConsensusBuy

Analysts Covering2

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS60471P1084

Price Chart

MIRO

Miromatrix Medical Inc. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

0.91 52WK RANGE 4.35

People Also View

Mineralys Therapeutics, Inc.

Eliem Therapeutics, Inc.

NervGen Pharma Corp.

Molecular Partners AG

Inhibikase Therapeutics, Inc.

AN2 Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message